Observational analysis shows a peptide-based degrader enhances response to PARP inhibitors in HR proficient prostate cancer, suggesting a new therapeutic strategy.
Supplementary Fig. S5. BPD sensitizes HR proficient prostate cancer cells to synthetic lethality by PARP inhibitors. Related to Fig. 5.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: